Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) 

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer^[1][2].

Mouse IgG1 kappa

Mouse IgG1 kappa, Isotype Control

Human/Mouse/Rat

PD-L1

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) (10 μg/mL, 2 days) increases IFN-γ levels in organoid-primed T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) (200 μg/rat, submucosally injection, twice a week at 16-20 week) alleviates mucosal lesions and the pathological impairment in 4-Nitroquinoline N-oxide (4NQO)‑induced oral squamous cell carcinoma (OSCC) rats models^[1].
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) (10 mg/kg, i.p., weekly for 6 weeks) significantly suppresses tumor growth in Nitroso-N-methylurea (NMU)-induced mammary tumor rats models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

60533  [NCBI]

Q9EP73

in vivo PD-L1 blockade; in vitro PD-L1 blockade; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) (HY-P990173, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103.  [Content Brief]

  [2]. Zhou J, et al. Tumor-colonized Streptococcus mutans metabolically reprograms tumor microenvironment and promotes oral squamous cell carcinoma. Microbiome. 2024 Oct 5;12(1):193.  [Content Brief]

  [3]. Gil Del Alcazar CR, et al. Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunol Res. 2022 Jun 3;10(6):680-697.  [Content Brief]